Preclinical analysis of oncolytic adenovirus infection to patient-derived tumor specimens of bone and soft tissue tumors

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10444
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: National Hospital Organization Shikoku Cancer Center (2017); Okayama University (2015-2016)
• Principal Investigator: Koji Uotani 独立行政法人国立病院機構四国がんセンター(臨床研究センター), その他部局等, 医師 (30708087)
• Co-Investigator(Kenkyū-buntansha): 尾崎 敏文 岡山大学, 医歯薬学総合研究科, 教授 (40294459) ; 藤原 俊義 岡山大学, 医歯薬学総合研究科, 教授 (00304303) ; 藤原 智洋 岡山大学, 医歯薬学総合研究科, 助教 (80639211)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肉腫 / ウイルス治療 / 腫瘍融解アデノウイルス

Outline of Final Research Achievements

The oncolytic adenovirus (Telomelysin) developed at our university replicates under the presence of CAR and hTERT for the expression of its effect, and it is necessary to evaluate the presense for screening of the adaptive case for clinical application of the viral therapy against the bone soft tissue tumor. TelomeScan was also developed at our university, which was integrated with GFP gene and emitted green fluorescence by intracellular virus multiplication. In this study,malignant bone soft malignant / intermediate malignant tumor was infected with TelomeScan and fluorescence expression was evaluated. The correlation between the fluorescence positive number at 24 hours after viral administration and the expression intensity of CAR was significantly observed. The expression of hTERT tended to be related to the enhancement of fluorescence time-dependently. The adaptable cases with sarcoma for Telomelysin could be evaluated only by administration of TelomeScan to clinical specimens.

Free Research Field

骨軟部腫瘍